ProMIS neurosciences raises $0.8 million in registered direct offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules
July 22, 2025 7:00 AM EDTCAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) -- Â ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzhiemers disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinsons disease (PD), today announced that it has raised $0.8 million at-the-market from an existing healthcare focused institutional investor.
The company has entered into a definitive agreement for the issuance and sale of pre-funded warrants (the Pre-Funded Warrants) to purchase 984,736 common shares, no par value (the Common Shares). The... More
